January 16,Zhongsheng PharmaceuticalAn Announcement Ignites the Metabolic Field – Its Holding SubsidiaryRaynoventAndQilu PharmaceuticalSign the "License Agreement" and authorizeQilu PharmaceuticalIn China(Including mainland China, Hong Kong, Macao, and Taiwan)Exclusive Production and Commercial SalesRAY1225 Injection, with a total amount as high as RMB 1 billion(Including down payment and milestone payments). This transaction is not only a milestone in the cooperation between the two parties, but also allowsGLP-1/GIPDual Receptor Agonist Field Welcomes Another "Heavyweight Player".

Screenshot source: Zhongsheng Pharmaceutical announcement

In the cooperation, the rights distribution model highlights innovation and foresight: Zhongsheng Pharmaceutical still retains full intellectual property rights of the product as well as overseas rights.

RAY1225 InjectionIt is a globally innovative polypeptide drug with a unique structure independently developed by Raynovent. Its core competitiveness lies in the dual advantages of "dual targets + ultra-long duration": it simultaneously exhibits dual agonistic activity on GLP-1 and GIP receptors, synergistically regulating insulin secretion, suppressing appetite, enhancing insulin sensitivity, and promoting energy expenditure. Its glucose control and weight reduction effects are superior to single-target drugs. Moreover, due to its excellent pharmacokinetic properties, it achieves an ultra-long-acting dosing regimen of once every two weeks (compared to the once-a-week dosing of mainstream GLP-1 drugs), significantly improving long-term medication adherence among patients and directly addressing key challenges in metabolic disease management.

This billion-level cooperation is not only a strategic move for Raynovent to expand its market with technology, but also an important piece in Qilu Pharmaceutical's efforts to strengthen its presence in the metabolic field. It also marks the official entry of domestically produced GLP-1/GIP dual-target drugs into a new phase of "commercialization race."

Currently,RAY1225 InjectionPhase III Clinical Trial for Safety and Efficacy in Treating Chinese Obese/Overweight Patients (REBUILDING-2 Study),RAY1225 InjectionThe Phase III clinical trial (SHINING-3) of the safety and efficacy of semaglutide injection in combination with oral hypoglycemic agents for the treatment of patients with type 2 diabetes, and the Phase III clinical trial (SHINING-2) of the safety and efficacy of RAY1225 injection as monotherapy for patients with type 2 diabetes, placebo-controlled, have successfully completed the enrollment of all participants.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Anti-HIV Drug Market Research Special Report - 202501

Market Research Report on Anti-Hepatitis Virus Drugs - 202501

Analysis of Complex Injectable Formulations Based on Dosage Form Improvement - Microspheres - 202501

Trends in Clinical Trials in China and the Outlook for International Multicenter Clinical Trials - 202505

Deployment Plan for AI Large Model-Based Pharmaceutical Knowledge Engineering System - 202504

Analysis Report on the Chinese Pharmaceutical Market H2 2023-H1 2024 - April 2025

2024 Healthcare Security Negotiation and Market Analysis Report - 202504

Top 100 List of Innovative Development of Chinese AI Medical and Health Enterprises - 202503

2024 China Class 1 New Drug Targets White Paper - 202503

More RecentlyMoso ConsultancyPopular Report, Scan the QR Code Below to Claim

Contact us to experience more professional services from Raynovent.
WillDiscussion CombinedWork	GardenZone TakeWu	Database Consultation	Customization Service	Media Cooperation

ClickReadRead the Original Text, apply for a free trial of Raynovent's enterprise version!